International Stem Cell Corporation (ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, said the USPTO granted the firm a key patent “on the method used to manufacture ISC-hpNSC.”
“These are the cells administered in ISCO’s ongoing Parkinson’s disease clinical trial, and they can potentially be utilized in therapies to treat traumatic brain injury and stroke,” said ISCO.
“This patent covers the procedure where human pluripotent stem cells (hpSCs), which have the potential to differentiate into essentially all cell types in the human body, are chemically differentiated into neural stem cells (NSCs), self-renewing cells that generate the neurons and glia of the central nervous system.”
Russell Kern, ISCO’s executive vice president and chief scientific officer, said: “Year after year, ISCO continues to strengthen its position as a leader in the field of regenerative medicine and explore the full potential of hpSCs.
“This new patent adds to the strong intellectual property of the company and positions us to extend our scientific reach to new heights.”